Published in Eur J Clin Pharmacol on April 28, 2004
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol (2010) 1.15
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol (2005) 1.06
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol (2010) 1.06
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther (2014) 1.03
Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol (2008) 1.00
Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol (2011) 0.91
Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol (2011) 0.88
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol (2009) 0.88
Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol (2004) 0.88
Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. Br J Clin Pharmacol (2015) 0.87
Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). EXCLI J (2014) 0.82
Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. J Clin Pharmacol (2008) 0.79
Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model. Drug Metab Dispos (2016) 0.79
Accelerator mass spectrometry-enabled studies: current status and future prospects. Bioanalysis (2010) 0.79
Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol (2015) 0.78
Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects. Eur J Clin Pharmacol (2005) 0.77
Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs. Dialogues Clin Neurosci (2016) 0.75
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics (2000) 2.17
The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther (1998) 1.72
Noninvasive tests of CYP3A enzymes. Pharmacogenetics (1994) 1.69
Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther (1996) 1.39
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther (1994) 1.36
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther (1999) 1.32
Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 1.30
Pencil and paper tests--sensitivity to psychotropic drugs. Br J Clin Pharmacol (1984) 1.26
Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther (1994) 1.22
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics (2001) 1.12
Single plasma sampling to predict oral clearance of CYP3A probe midazolam. Acta Pharmacol Sin (2001) 0.98
Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther (1997) 0.94
Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects. J Clin Pharmacol (2002) 0.92
Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics (1999) 0.92
Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res (2003) 0.89
Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther (1998) 0.87
Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe. Clin Pharmacol Ther (2000) 0.85
Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Ther Drug Monit (1998) 0.84
Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther (1997) 0.83
Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.83
Concentrations and effects of zopiclone are greatly reduced by rifampicin. Br J Clin Pharmacol (1997) 0.80
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
WGAViewer: software for genomic annotation of whole genome association studies. Genome Res (2008) 7.15
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis (2008) 5.39
Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol (2010) 4.34
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol (2008) 3.53
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med (2003) 3.41
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med (2003) 3.37
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol (2009) 3.05
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics (2005) 2.94
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther (2004) 2.81
Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe (2012) 2.66
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol (2007) 2.60
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology (2009) 2.59
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis (2005) 2.58
Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature (2011) 2.36
SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood (2013) 2.18
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis (2012) 2.11
Safe and effective variability-a criterion for dose individualization. Ther Drug Monit (2012) 2.08
How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart (2011) 2.06
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther (2003) 2.05
Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med (2005) 2.04
Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol (2012) 2.03
APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol (2004) 1.97
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet (2002) 1.96
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res (2004) 1.95
Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet (2003) 1.94
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis (2005) 1.93
Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog (2010) 1.90
French validation of the internet addiction test. Cyberpsychol Behav (2008) 1.90
24 hours in the life of HIV-1 in a T cell line. PLoS Pathog (2013) 1.89
BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology (2004) 1.88
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 1.87
Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med (2005) 1.83
Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS (2006) 1.81
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med (2007) 1.80
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics (2009) 1.79
HIV entry inhibitors. Lancet (2007) 1.73
CCL3L1 and HIV/AIDS susceptibility. Nat Med (2009) 1.73
Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (2003) 1.70
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood (2010) 1.70
Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J Virol (2004) 1.68
Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog (2010) 1.63
The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. AIDS (2004) 1.63
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS (2002) 1.63
Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med (2004) 1.62
Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest (2011) 1.61
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology (2007) 1.61
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother (2006) 1.61
Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy. PLoS One (2011) 1.58
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther (2002) 1.58
Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics (2004) 1.56
Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol (2006) 1.54
Lausannevirus, a giant amoebal virus encoding histone doublets. Environ Microbiol (2011) 1.53
Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut (2010) 1.53
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics (2010) 1.46
Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology (2006) 1.46
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection. Blood (2002) 1.45
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther (2005) 1.45
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis (2010) 1.45
Copy number variation of KIR genes influences HIV-1 control. PLoS Biol (2011) 1.44
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med (2003) 1.44
Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. J Clin Psychopharmacol (2012) 1.44
Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics (2007) 1.43
Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. AIDS (2002) 1.41
Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos (2002) 1.40
Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. J Virol (2010) 1.40
Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS (2007) 1.39
Spare non-occupational HIV post-exposure prophylaxis by active contacting and testing of the source person. AIDS (2002) 1.39
Drug resistance mutations in HIV-1. Top HIV Med (2004) 1.37
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther (2004) 1.33
Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. J Infect Dis (2004) 1.33
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey. J Clin Microbiol (2003) 1.33
Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol (2007) 1.31
Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther (2004) 1.30
Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology (2011) 1.30